Skip to main content

Peer Review reports

From: A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

Original Submission
10 Oct 2019 Submitted Original manuscript
12 Nov 2019 Author responded Author comments - Sebastien Perreault
Resubmission - Version 2
12 Nov 2019 Submitted Manuscript version 2
23 Nov 2019 Author responded Author comments - Sebastien Perreault
Resubmission - Version 3
23 Nov 2019 Submitted Manuscript version 3
4 Dec 2019 Author responded Author comments - Sebastien Perreault
Resubmission - Version 4
4 Dec 2019 Submitted Manuscript version 4
Publishing
8 Dec 2019 Editorially accepted
27 Dec 2019 Article published 10.1186/s12885-019-6442-2

You can find further information about peer review here.

Back to article page